These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17766002)

  • 1. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
    Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Park YH; Lee SY; Lee JS
    Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
    Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
    Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
    Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
    Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
    J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
    Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
    Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
    Xiang X; Jada SR; Li HH; Fan L; Tham LS; Wong CI; Lee SC; Lim R; Zhou QY; Goh BC; Tan EH; Chowbay B
    Pharmacogenet Genomics; 2006 Sep; 16(9):683-91. PubMed ID: 16906022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.
    Takane H; Miyata M; Burioka N; Kurai J; Fukuoka Y; Suyama H; Shigeoka Y; Otsubo K; Ieiri I; Shimizu E
    Ther Drug Monit; 2007 Oct; 29(5):666-8. PubMed ID: 17898662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.
    Rohrbacher M; Kirchhof A; Skarke C; Geisslinger G; Lötsch J
    Pharmacogenomics; 2006 Mar; 7(2):167-76. PubMed ID: 16515396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
    Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
    Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
    Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
    Takane H
    Yakugaku Zasshi; 2011; 131(11):1589-94. PubMed ID: 22041697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
    Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
    Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
    Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB
    Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLCO1B1 polymorphism and oral antidiabetic drugs.
    Kalliokoski A; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.
    Yamamoto N; Takahashi T; Kunikane H; Masuda N; Eguchi K; Shibuya M; Takeda Y; Isobe H; Ogura T; Yokoyama A; Watanabe K
    Clin Pharmacol Ther; 2009 Feb; 85(2):149-54. PubMed ID: 18685565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
    Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.